Prostate Cancer: is a cancer in a man's prostate, a small walnut-sized gland that produces seminal fluid. Some types of prostate cancer grow slowly, and other types are aggressive and require radiation, hormone therapy, surgery, chemotherapy, or other treatments.
DATE: November 10, 2016
TIME: 9:00am PT, Noon ET
The CellSimple™ Cell Analyzer enables quick and easy research assays, including functional cell-based assays, cell-model...
DATE: November 4, 2016
TIME: 10:00am PT, 1:00pm ET
How do you develop clinically relevant biomarkers?
Systematic tumor profiling with multi-omics tools and rapid analytical...
Vitamin D3 supplementation can effectively remedy the current epidemic of vitamin D deficiency, especially within the African-American population and the elderly of any ethnicity. Racial disp...
Over the past 6 years, a number of agents, all mechanistically different, have been approved with a statistically significant survival benefit as monotherapy for treatment of metastatic castr...
DATE: August 11, 2016
TIME: 11:00AM PST, 2:00PM ET, 7:00PM GMT
The central dogma that forms the backbone of molecular biology is that DNA codes for RNA (transcription) which then c...
DATE: July 20thTIME: 8AM PT, 11AM ET, 5PM CESTTherapies like ipilimumab and nivolumab have shown the potential for approaches that direct the patient’s own immune system aga...
DATE: June 15, 2016TIME: 08:00AM PDT, 11:00AM EDT, 3:00PM GMT Positron Emission Tomography (PET) is a 3-dimensional, quantitative imaging technology that has robust clinical trans...
DATE: June 9, 2016
TIME: 9am Pacific time, 12pm Eastern time
Complex cell and bead-based assays are simple and fast with the CellSimple™ Cell Analyzer. This instrument combine...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways e...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Precision medicine requires understanding the mechanistic basis of complex disorders, and to precisely manipulate these mechanisms to better human health. This is partly enabled by the recent...
DATE: January 26th, 2016
TIME: 8am pacific, 11am eastern
PTEN gene loss occurs frequently in castration-resistant prostate cancer (CRPC) and may drive progression through activation of th...
Cancer-derived extracellular vesicles (EVs) play an important role in cancer progression and metastasis. They can be identified in biological fluids thus providing appealing candidates for no...
This lecture will provide attendees with the knowledge and skills to bring on new clinical laboratory tests in clinical chemistry and molecular diagnostics. The lecture will provide a general...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
This presentation discusses the advantages and disadvantages of robotic surgery. The initial goals for a robotic prostatectomy will be discussed as well as patient expectations and outcomes.&...
The management of prostate cancer (PCa) continues to evolve and does so at a rapid rate. Research and technological developments continue to refine our definitions and management of this comp...
The burgeoning area of molecular risk assessment (gene expression profiling and/or proteomic tests) in the diagnosis and treatment of prostate cancer is rapidly illuminating how clinicians mi...
The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prio...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
DATE: November 10, 2016
TIME: 9:00am PT, Noon ET
The CellSimple™ Cell Analyzer enables quick and easy research assays, including functional cell-based assays, cell-model...
DATE: November 4, 2016
TIME: 10:00am PT, 1:00pm ET
How do you develop clinically relevant biomarkers?
Systematic tumor profiling with multi-omics tools and rapid analytical...
Vitamin D3 supplementation can effectively remedy the current epidemic of vitamin D deficiency, especially within the African-American population and the elderly of any ethnicity. Racial disp...
Over the past 6 years, a number of agents, all mechanistically different, have been approved with a statistically significant survival benefit as monotherapy for treatment of metastatic castr...
DATE: August 11, 2016
TIME: 11:00AM PST, 2:00PM ET, 7:00PM GMT
The central dogma that forms the backbone of molecular biology is that DNA codes for RNA (transcription) which then c...
DATE: July 20thTIME: 8AM PT, 11AM ET, 5PM CESTTherapies like ipilimumab and nivolumab have shown the potential for approaches that direct the patient’s own immune system aga...
DATE: June 15, 2016TIME: 08:00AM PDT, 11:00AM EDT, 3:00PM GMT Positron Emission Tomography (PET) is a 3-dimensional, quantitative imaging technology that has robust clinical trans...
DATE: June 9, 2016
TIME: 9am Pacific time, 12pm Eastern time
Complex cell and bead-based assays are simple and fast with the CellSimple™ Cell Analyzer. This instrument combine...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways e...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Precision medicine requires understanding the mechanistic basis of complex disorders, and to precisely manipulate these mechanisms to better human health. This is partly enabled by the recent...
DATE: January 26th, 2016
TIME: 8am pacific, 11am eastern
PTEN gene loss occurs frequently in castration-resistant prostate cancer (CRPC) and may drive progression through activation of th...
Cancer-derived extracellular vesicles (EVs) play an important role in cancer progression and metastasis. They can be identified in biological fluids thus providing appealing candidates for no...
This lecture will provide attendees with the knowledge and skills to bring on new clinical laboratory tests in clinical chemistry and molecular diagnostics. The lecture will provide a general...
Cancer is complex, but recent findings are yielding a greater understanding of the disease. The tumor suppressor genes BRCA1 and BRCA2 are implicated in breast, ovarian, prostate, and other c...
This presentation discusses the advantages and disadvantages of robotic surgery. The initial goals for a robotic prostatectomy will be discussed as well as patient expectations and outcomes.&...
The management of prostate cancer (PCa) continues to evolve and does so at a rapid rate. Research and technological developments continue to refine our definitions and management of this comp...
The burgeoning area of molecular risk assessment (gene expression profiling and/or proteomic tests) in the diagnosis and treatment of prostate cancer is rapidly illuminating how clinicians mi...
The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prio...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Follow
